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ABSTRACT 
The aim if this study is to explore the impact of the various prognostic factors on overall survival in women with ovarian cancer (OC). 
Patients diagnosed with gynecologic malignancy in Gynecology Clinic of Baskent University Medicine Faculty between 2010 and 2015 
included to study. Patients with ovarian (n= 112) cancers examined retrospectively. Kaplan-Meier, Univariate and Multivariate Cox re-
gression model were performed to estimate for associations of potential variables with survival factors. The mean patient age was 56.4 
y, range 20-80. The overall survival was 94.3%, 83.4%, 66.4%, 54.7% and 42.8% at 1, 2 3, 4 and 5 years respectively (60.5 months, 
range 43-68). 3-year disease-free survival was 25.3% (18.3 months, range 17-20). Multivariate analysis of patients indicated that stage, 
histology, grade, age at diagnosis, comorbidity, recurrence, BMI, menopausal status and regional distance were independent prognos-
tic factors on survival (p< 0.05). In conclusion, these results will presents a framework to identify fundamental causes in survival for OC. 
Keywords: Ovarian cancer, 5-year survival, Prognostic factors
ÖZET 
Over Kanserli Hastalarda Sağkalımı Etkileyen Prognostik Faktörler: Bir Üniversite Hastanesinin 5 Yıllık Deneyimi
Bu çalışmanın amacı, over kanseri (OK) hastalarında sağkalımı etkileyen prognostik faktörleri araştırmaktır. Çalışmada, 2010 ile 
2015 yılları arasında Başkent Üniversitesi Tıp Fakültesi Hastanesi Jine-Onkoloji Bölümü’nde tanı alan 112 over kanserli hasta ret-
rospektif olarak incelenmiştir. Sağkalım süreleri hesaplanırken Kaplan-Meier metodu ve sağkalımı etkileyen faktörlerin ilişkisini ke-
stirmek amacıyla Çok yönlü ve Tek yönlü Cox Regression modeli kullanılmıştır. Hastaların ortalama yaşı 56.4 (20-80)’dür. Genel 
sağkalım oranları sırasıyla; 1 yıllık-%94.3, 2 yıllık-%83.4, 3 yıllık- %66.4, 4 yıllık-%54.7 ve 5 yıllık- %42.8 (65.5±6.2 months)’dir. 3 yıllık 
hastalıksız sağkalım oranı %25.3 (18.3±3.94 months)’dir. Çok değişkenli analize göre, hastaların tanı aldığı yaş, BKİ, komorbidite, 
evre, grade, histoloji, rekürrens, menopoz durumu ve bölgesel uzaklığın OK hastalarının sağkalımı üzerinde etkili olduğu bulundu (p< 
0.05). Bu çalışmanın sonucunda elde edilen bulgular, OK sağkalımının temel nedenlerini belirlemede önemli bir çerçeve sunacaktır. 
Anahtar Kelimeler: Over kanseri, 5 yıllık sağkalım, Prognostic faktörler
*= Formerly
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INTRODUCTION
Ovarian cancer (OC) is the deadliest gynecologic 
cancer worldwide, with nearly 225.000 new cases 
diagnosed each year and 140.000 deaths annu-
ally.Lifetime risk of OC in women is one in 71, 
and the risk of dying from the disease is 1 in 95.1 
Based on GLOBOCAN estimates, the incidence 
and mortality of OC varies in different regions 
of the world; Scandinavian (14.9/100000), USA 
(13.3/100000), UK (11.7/100000), Russian Fed-
eration (11.3/100000), and Japan (4.8/100000).2 
In Turkey (6.6/10000), OC is also a major health 
problem in women following breast cancer. This is 
higher than that of the previous reports in Turkey.3
Regrettably, identifying this disease is difficult. 
There is no routine, screening test to accurately 
and reliably detect OC in the general population 
so diagnosis of OC in the advanced stages leads 
to this cancer being considered as a fatal disease. 
Although the incidence and mortality of this dis-
ease is high, its prognostic factors are still not com-
pletely understood especially in low-income coun-
tries.4,5 In the literature, survival depends on many 
factors such as patient’s family history, multiple 
comorbidities, postoperative complications, chem-
otherapy toxicities, increasing age, postmenopau-
sal period, recurrence, presence of positive lymph 
nodes, advanced stage and grade, carcinosarcomas 
subtype, ascites, never having been pregnant and 
having never taken oral contraceptives, as well as 
lifestyle factors such as performance status, smok-
ing and obesity.6-11
Statistics show that survival from all cancers in 
women was 64.2% while it was approximately 
45.0% for OC globally and the 5-year survival rate 
has improved in OC by only 9% since 1975 even 
in high-income countries.2 A 5-year survival rate 
is about 43% in Turkey (1970s-37%, 1980s-40%, 
and 2000s-45%).3 Despite the recently improve-
ments such as advances in the diagnosis, staging, 
and treatment of OC, and provided significant ad-
vancement of patients survival, major challenges 
related to the prognostic implications of its clinic-
pathologic characteristics remain controversial in 
the management of OC. Most women with OC 
are likely living with the disease rather than liv-
ing cancer-free and some oncologists consider OC 
a chronic disease.9,12 Relatively, limited compre-
hensive national information describing clinical 
and nonclinical factors associated with survival is 
available in Turkish women with OC. Therefore, 
estimating survival is remarkable that provide an 
understanding of the disease course and better 
prognosis for OC. 
PATIENTS AND METHODS
The aim of this study was to investigate determi-
nant factors associated with survival of women 
with OC over the course of five years. The popula-
tion of the study consisted of all patients with OC 
in years 2010-2015 who were actively followed-up 
and age 18 years or older were included at the Gy-
necologic Oncology Clinic, Faculty of Medicine, 
Baskent University Hospital (n= 112). Patients 
with unknown treatment data, or missing infor-
mation were excluded. In addition, patients who 
survived less than 12 months after diagnosis were 
excluded to limit bias. Patients were scheduled for 
follow-up every two months in the first year, every 
three months during the second year and every six 
months thereafter. Follow-up data such as date of 
last visit and disease status at the time of the last 
contact were also noted. This study was conducted 
at a multidisciplinary tertiary care center. The re-
search was approved by the University of Baskent 
Institutional Review Board and was conducted in 
compliance with principles of Helsinki declaration.
The data were collected by using three differ-
ent forms between April 2016 and January 2016 
through hospital-based cancer registry; 1) The Pa-
tient Information Form, 2) The Charlson Comor-
bidity Index (CCI), and 3) The Eastern Coopera-
tive Oncology Group (ECOG) Performance Scale. 
1. The Patient Information Form
This form includes 21 questions to define individ-
ual and medical characteristics of the women with 
OC such as patient age at diagnosis, educational 
level, occupation, marital status, family income, 
smoking history, alcohol use history, family his-
tory, distance of patient travel, residence, survival 
time information, clinic-pathological character-
istics (stage, grade, cell subtype, recurrence, re-
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hospitalization and readmission, primary surgery, 
treatment modality, treatment toxicities, preopera-
tive CA125, postoperative and intraoperative com-
plications). Histology was classified based on the 
International Classification of Diseases for Oncol-
ogy (ICD-O) as serous, mucinous, endometrioid, 
clear cell; and tumor grade as well differentiated, 
moderately differentiated or poorly differentiated. 
Stage categories were based on the International 
Federation of Gynecology and Obstetrics (FIGO) 
stages I, II III and IV. Survival time was calculated 
from date of diagnosis until death or censoring. 
The overall survival (OS) was defined as the time 
from first diagnosis to death or the date of last fol-
low up. Disease-free survival (DFS) is the time 
elapsed from PE to first recurrence and OS is the 
time from PE to the last follow-up date or death. 
BMI values of patients were classified as under-
weight (BMI <18.5 kg/m2), normal (BMI 18.5-
24.9 kg/m2), overweight (BMI 25-29.9 kg/m2), and 
obese (BMI ≥30 kg/m2) according to World Health 
Organization (WHO) criteria.13
2. The Charlson Comorbidity Index (CCI)
Comorbidity was measured for each patient using 
the Charlson Comorbidity Index (CCI), catego-
rized as 0, 1, or ≥2, with a higher score indicating 
a larger number or greater severity of comorbidi-
ties.14 The CCI, ranging from 0 to 29, consists of 
a weighted sum of 17 major illnesses (e.g., myo-
cardial infarction, stroke, diabetes, liver disease, 
dementia, renal disease). HT was included in the 
list of possible comorbid illnesses.
3. European Cooperative Oncology Group 
(ECOG) Performance Scale
This scale was developed by the Eastern Coopera-
tive Oncology Group (ECOG) in 1982 to classify 
a patient according to their functional impairment, 
compare the effectiveness of therapies, and assess 
the prognosis of a patient (from 0 to 5, with 0 de-
noting perfect health and 5 death).15
Statistical Analysis
Descriptive statistical analyses were performed 
with SPSS version 18 (SPSS inc., Chicago, IL). 
Categorical variables were compared using Pear-
son chi-square test and continuous variables using 
the Wilcoxon–Mann–Whitney and Kruskal–Wallis 
tests. Survival was estimated using the Kaplan–
Meier method. Univariate and multivariate Cox 
Regression model (95% CIs) were used to evaluate 
the effects of multiple prognostic factors on sur-
vival.16 The significance level was p< 0.05.
RESULTS
There were 112 patients who met inclusion crite-
ria. The patients’ general characteristics are shown 
in Table 1. The median age at diagnosis was 56.4 
years + 11.3 (min: 20 - max: 80). Findings deter-
mined that 56.2% were primary school graduates, 
Table 1. Demographics for women with OC 
Demographics n %
Age at diagnosis (Mean: 56.4, range 20-80) 
 < 40 16 14.3
 40-60 61 54.3
 > 60 35 31.3
Education status  
 Primary  school 63 56.2
 High school or higher  49 43.8
Marital status  
 Married 97 86.6
 Single  15 13.4
Employment status  
 Yes  23 20.3
 No  89 79.7
Income status  
 Good  8 7.1
 Medium 76 67.9
 Poor 28 25.0
Parity (Mean: 3.3, range 0-10)  
 0 15 13.4
 1-3 54 58.2
	 ≥	4		 43	 28.4
Region are of residence  
 Rural 15 13.4
 Urban  97 86.6
Distance from residence to hospital, miles (Mean: 210, range 
0-750) 
 0-12.49 28 25.0
 12.5-49.9  9 8.0
 50-249  6 5.4
	 ≥	250	 69	 61.6
Smoking  
 Yes (>10 pack-days) 30 26.8
 No (Never) 82 73.2
Total 112 100.0
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79.7% were housewives, 86.6% were married, 
67.9% had their income equal to expenditure, and 
86.6% were urban dwellers. The mean parity was 
3.35, ranging from 0 to 10. All of the women had 
health insurance, 73.2% did not smoke (99.5% 
did not drink alcohol). Distance from residence to 
center, miles (range) was 210±10.2 (0-750) (Table 
1).
Seventy percent of women were diagnosed during 
menopause (the rate of surgically induced meno-
pause was 34.8%). More than half of women were 
obese (56.3%). The majority of women had a car-
egiver (85.7%). One in three received psychologi-
cal support for their illnesses. Thirty-three percent 
of women had cancer stories in their families and 
Table 2. Medical characteristic for women with OC 
Variables n %
Menopausal status (Mean: 48.8, range 26-55 y)  
 Premenopausal 34 30.4
 Postmenopausal 78 69.6
Type of menopausal  
 Natural 73 65.2
 Surgery  39 34.8
BMI  
 Normal (18.5-24.9 kg/ m2) 49 43.8
	 Overweight	+	Obese	(≥25	kg/m2)	 63	 56.3
Caregiver support  
 Yes  96 85.7
 No  16 14.3
Psychological support  
 Yes  34 30.4
 No  78 69.6
Gynecological cancer in the family history
 Yes  13 11.6
 No  99 88.4
Cancer in the family history  
 Yes  37 33.0
 No  75 67.0
Previous surgery history  
 Yes  54 48.2
 No   58 51.8
CCI  
 0 40 35.7
 1 54 48.2
	 ≥	2		 18	 16.1
Total 112 100.0
Abbreviations: BMI: Body mass index, CCI: Charlson Comorbidity 
Index
Table 3. Cancer and treatment characteristic for women with 
OC 
Variables n %
Initial symptoms at first admission  
 Abdominal-pelvic pain 22 19.6
 Vaginal bleeding-irregular menstrual cycle 40 35.7
 Abdominal distension 50 44.6
Stage   
 1-2 30 17.8
 3-4 92 82.2
Grade  
 1/2  38 33.9
	 ≥	3		 72	 66.1
Subtype  
 Serous  85 75.9
 Endometrioid 16 13.2
 Mucinous 6 6.4
 Clear cell 5 4.5
Primary surgery  
 USO + BPPLND + Omentectomy 9 8.0
 TAHBSO 12 10.7
 TAHBSO + BPPLND +  91 81.3
    Omentectomy
Other treatments  
 CT 88 78.6
 RT 23 20.5
 CT+RT 11 9.9
CT+RT Toxicities  
 Yes  96 85.7
 No   33 29.4
ECOG  
 0-1 74 66.1
 2-3 38 33.9
Preop CA12-5  
 35-500 85 75.9
	 ≥	500	 27	 24.1
Recurrence   
 1  71 63.4
 >1 41 36.6
Postoperative complication  
 Yes  21 18.7
 No  91 81.3
Intraoperative complication  
 Yes   8 6.2
 No  104 92.8
Unplanned readmission at least one (hospitalized -76%)
 Yes  69 61.6
 No  43 38.4
Abbreviations: CA125: Serum cancer antigen 125, CT: Chemothera-
py, RT: Radiotherapy, USO: Unilateral Salpingo-Oophorectomy, TAH-
BASO: Total Abdominal Hysterectomy and Bilateral Salpingo-Oopho-
rectomy, BPPLND: Bilateral pelvic and paraaortic lymphadenectomy
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eleven-one percent of women had gynecological 
cancer stories in their families. Among patients 
with OC, 35.7% had an CCI- 0, and 48.2% had an 
CCI- 1, (28.2%) had an CCI -2 (16.1%), had an 
CCI-3 (8.5%) (Hypertension also has been identi-
fied as 48.6%). %48.2 patients had previous sur-
gery (Cesarean section 29.5%, cholecystectomy 
14.3%, and thyroidectomy 6.3%) (Table 2).
Primary surgery was performed on 112 patients 
during this 5-year period (secondary cytoreductive 
surgery was performed on all of the patients and 
nearly half of the patients underwent tertiary cytro-
ductive surgery) and was removed all visible tu-
mor. 91 patients; TAHBSO + BPPLND + omentec-
tomy, 12 patients; only TAHBSO, 9 patients; USO 
+ BPPLND + omentectomy (as additional surgery; 
41 patients appendectomy; 8 patients cholecystec-
tomy; 12 patients splenectomy; 6 patients colon 
resection + colostomy. Hospital length of stay after 
surgery was 13.14±4.64. Postoperative complica-
tions were seen in 21 patients (18.7%) (within 4 
weeks after surgery). These complications were 
fewer (18.6%), wound evisceration (4.5%), res-
piratory complication (3.3%), ileus (11.3%), DVT 
(16.3%), lymphocele (3.2%). Rate of intraoperative 
complication was 8.4% (defects in the bowel se-
rosa during surgery). Readmission rate was 61.6%. 
Patterns of unplanned readmission in patients 
were deep vein thrombosis-DVT (19.6%), pyrexia 
(60.7%), acute abdomen (29.6%), genital tract in-
fection (22.3%), pain and weakness (56.3%), dysp-
nea (7.4%) and ileus (22.3%) (Table 3).
Most (82.2%) had stage III or IV cancer (all of 
them were epithelial type OC). More than half 
the cancers (75.9%) were serous subtype and 
66.1% were high-grade (≥ 3). All of patients un-
derwent primary surgery (The mean operative 
time was 120 minutes). 85.7% of patients received 
CT (median cure was 6.2+3.3) (platinum-taxane 
-paclitaxel+carboplatin 88.3%, cisplatin/ gemcit-
abine 8% and doxorubicin + carboplatin 6%) and 
only 20.5% RT. ECOG performance status was “0-
1” (66.1%), “≥2” (33.9%) in patients’ last hospital-
izations (Table 3). Hematologic and non-hemato-
Table 4. Distributions of OS and DFS scores
Years (y) Overall survival Disease-free survival  
 (OS) (DFS)
1 y 94.3% 68.7%
2 y 83.4% 33.4%
3 y 66.4% 15.3%
4 y 54.7% -
5 y  42.8% -
Median  60.5 months 18.3 months
(%95 GA)  (range 43-68) (range 10-27)
 (95%CI)  (95%CI)
Table 5. Univariate Cox regression model of OS 
Variables HR %95 CI P
Age	at	diagnosis	(≤40y	vs	>40y)	 1.78	 1.20-1.85	 0.015
Stage (III-IV vs I-II)  1.38 1.28-2.91 0.001
Recurrence (1 vs >1) 1.64 1.50-1.93 0.001
BMI	(≥25	kg/m2 vs <25 kg/m2) 1.22 1.15-1.32 0.004
Subtype (serous vs others)  1.07 1.10-1.28 0.001
Menopausal status (pre vs post) 1.50 1.14-1.61 0.017
Tumor	grade	(1-2	vs	≥	3)	 1.03	 1.23-2.39	 0.001
Cancer in family history (yes vs no) 1.52 1.11-2.15 0.032
ECOG	(0-1	vs	≥2)	 1.10	 1.00-1.35	 0.002
Comorbidity	(0-1	vs	≥2)	 1.31	 1.20-1.46	 0.001
Residence	distance	(≤	50	miles	vs	>	50	miles)	 1.29	 1.02-1.33	 0.021
HR: hazard ratio, CI: Confidence Interval
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logic toxicity of the CT and RT comprised anemia 
(29.7%), neutropenia (28.6%), thrombocytopenia 
(26.3%), pain (33.4%), alopecia (48.9), diarrhea 
(18.4%), nausea/ vomiting (38.4%), and oral mu-
cositis (13.7%). No patient was lost to follow-up.
The OS for patients was 60.5 months and the medi-
an DFS rate was 18.3 months. The 1-year survival 
rate was 94.3%, 2-year survival rate was 83.4%, 
3-year 66.4%, 4-year 54.7%, and 5- year 42.8%. 
DFS scores were 1-year 68.7%, 2-year 33.4%, 
and 3-year 15.3 % (Table 4). Univariate model re-
vealed that the menopausal status, age at diagnosis, 
the FIGO stage, grade, histological type, perfor-
mance status, recurrence, BMI, residence distance, 
cancer in the family history and the comorbidity 
were related with OS significantly (Table 5). On 
multivariate analysis, advanced age was signifi-
cantly associated with worse OS (HR, 1.3 [95% CI, 
1.2-1.4] than younger women. Mucinous, endome-
trioid and clear cell subtypes were associated with 
worse OS than serous cancers (HR, 1.2 [95% CI, 
1.1-1.3]). Postmenopausal period (HR, 1.2  [95% 
CI, 1.2–1.8), obesity (HR, 1.1 [95% CI, 1.1-1.2), 
presence of recurrence (HR, 1.4 [95% CI, 1.0–1.3), 
and higher comorbidity scores (≥ 2), higher grade 
(HR, 1.1 [95% CI, 1.4-2.3) and stage (HR, 2.0 
[95% CI, 1.0-2.8) had significantly poorer OS rates 
(HR, 1.6 [95% CI, 1.1-2.1). Regional–remote resi-
dence were also associated with poorer OS (HR, 
1.3 [95% CI, 1.2-1.4]) (Table 6).
Compared to good prognosis women, poor progno-
sis women were less educated, and income level, 
had before surgery, high toxicity, and re-hospital-
ization. However, there was no significant differ-
ence in OS between the groups (p> 0.05). There 
were no major differences in distribution of other 
prognostic factors (p> 0.05).
DISCUSSION
OC is often called the silent killer; women often 
ignore early signs because there are no clearly 
identifiable initial symptoms often confused with 
complaints of common benign gastrointestinal dis-
orders such as abdominal distension and pain due 
to acidity. Because of diagnostic challenges only 
one fifth of OC patients are detected at the local-
ized stage. Frequently, women are medically man-
aged for indigestion or other complaints without 
having a pelvic examination, thus significant de-
lays before diagnosis are very common.4,5
In our study abdominal distension was seen in 
44.6% of patients, which was followed by abdomi-
nal/pelvic pain with a rate of 19.6%, and vaginal 
bleeding/irregular menstrual cycles was found in 
35.7%. In accordance with our study Oge et al7 
also reported abdominal swelling as the most com-
mon complaint (59.1%), and the second most fre-
quent complaint was reported as abdominal pain 
Table 6. Multivariate Cox regression model of OS 
Variables HR %95 CI P
Age	at	diagnosis	(≤	40y	vs	>	40y)	 1.37	 1.26-1.46	 0.009
Stage (III-IV vs I-II)  2.01 1.02-2.84 0.003
Recurrence (1 vs >1) 1.84 1.05-1.33 0.001
BMI	(≥25	kg/m2 vs <25 kg/m2) 1.15 1.17-1.29 0.005
Subtype (serous vs others)  1.23 1.16-1.30 0.001
Menopausal status (pre vs post) 1.32 1.28-1.87 0.010
Tumor	grade	(1-2	vs	≥	3)	 1.16	 1.43-2.30	 0.007
Higher	comorbidity	(0-1	vs	≥2)	 1.65	 1.11-2.13	 0.002
Residence	distance	(≤	50	miles	vs	>	50	miles)	 1.36	 1.26-1.43	 0.009
HR: hazard ratio, CI: Confidence Interval
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(20.8%). Physician and nurses recommendations 
regarding alarming symptoms and screening pro-
grams in this population are a vital investment on 
survival for OC. In addition there is a real need for 
new, more effective screening options for women 
with OC.
Cancer statistics often use 5-year OS rate to pre-
sent a better idea of the longer-term outlook for 
people with cancer.5 We found that the OS for OC 
was 94.3%, 66.4%, and 42.8% at 1, 3, and 5 years, 
respectively. Also, the median OS time was 60.5 
months. The slope of decline in OS was reduced 
during the first years after diagnosis. Most patients 
diagnosed with OC, survival is theorized to be 
100%, who are still alive after 5-years, are presum-
ably living with the disease rather than living dis-
ease-free.5 Our analysis demonstrated that the DFS 
was 18.3 months (10-27). The Surveillance, Epi-
demiology and End Results-SEER database from 
1995 to 2007 with epithelial OC who were ac-
tively followed-up and age 20 years or older were 
included for analyzing OS in the United States 
(40.692 patients) and OS was 65%, 44%, and 36% 
at 2, 5, and 10 years, respectively.10 Bailey et al.17 
evaluated the 5-year outcome of women (n= 361) 
with advanced OC in the South West of England 
as stage III was 16% and with stage IV was 10%. 
Recent prospective and randomized trials demon-
strated that patients with advanced OC (n= 718) 
from 1998 through 2006 at 59 institutions in Cana-
da have similar survival (OS: 29-30 months, DFS: 
12 months).18 In a study the median DFS and OS 
for patients with OC were 35.0 months and 54.0 
months respectively.19 In different study done by 
Anuradha et al in 2014, 1192 Australian women di-
agnosed with invasive epithelial OC in 2005 were 
identified through state-based cancer registries and 
the 5-year OS was 53%.20 A Swedish study pub-
lished in 2009 of 682 patients with epithelial OC 
found a 10-year relative survival rate of 38.4%, the 
median OS time was 81 months (52-109 months) 
in OC patients.6 Larger population-based analyses 
of 10-year OS in OC have not been published in 
the Turkish populations. In a study performed in 
Turkey, according to the surgical stages I, II, III 
and IV median survival was 78.5 months, 60.1 
months, 33.9 months and 16.1 months respectively 
and significantly different.7 In a study by Karaca21 
study, a number of 13.590 women (from 9 nation-
wide cancer registry centers) were evaluated who 
got gynecological cancer diagnosis (31.2% OC) 
in Turkey between 2004 and 2011, overall 5-year 
observed OC survival rate was 46%. Buldanlı et 
al reported that OS was 51.6% in Western Turkey. 
When we compare the all of results with national 
or international studies, the 5-year survival rate in 
our study did not differ from the 5-year survival 
published from the general population. 
Previous studies have shown that the survival of 
OC is affected by personal history, and genetic fac-
tors including low socioeconomic status, and life 
style.18,22-26 We scrutinized the analyzing related to 
various prognostic factors for OC. In the present 
study younger women, those diagnosed before 
the age of 40, had significantly better survival af-
ter five years than women diagnosed at older ages 
(p< 0.05). Older age at diagnosis was often asso-
ciated with comorbidities and functional deficits 
that impact their survival. Gershenson et al27 re-
ported on a cohort of 112 patients with stage II-IV 
low-grade serous carcinoma from M.D. Anderson 
Cancer Center in 2006, and noted age older than 
45 years at diagnosis was associated with longer 
survival. Some studies reported that increasing 
age was most strongly associated with poor sur-
vival.9,10,18-20,22 However, in the other studies of Oge 
et al7 and Buldanlı et al11 revealed that age was not 
was not effected by the age of the patients in OC.
Recently, treatments for cancer has resulted in 
increasingly complex care patterns and individu-
alization of care by multidisciplinary teams. Lack 
of access to a qualified region for proper oncol-
ogy center may impact outcome and contribute to 
disparities in early stage cancer. Access to on site 
appropriately qualified healthcare center is essen-
tial to decrease distance barriers and to improve 
survival.22 Conversely, Shylasree et al28 analyzed 
that there were no significant differences survival 
between women managed in the cancer center and 
those managed in the peripheral units. In our study, 
the patients are referred to the study hospital be-
cause they do not have a high-quality healthcare 
setting in the periphery. In our study, patients who 
traveled less than 50 miles for their cancer care 
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were more often favorable prognosis than patients 
who had traveled more than 50 miles (p< 0.05). 
Similarly, Anuradha et al20 reported that regional 
distance (HR, 1.2 [95% CI, 1.0-1.4]) was also asso-
ciated with poorer OS. A Cochrane Review by Woo 
et al24 in 2012 identified five studies (total 62.987 
women with gynecological cancer), and concluded 
that women with advanced OC may have improved 
outcomes if treated in specialist centers (in a two-
fold). In the light of this information, these results 
would be important for future studies to assess the 
survival associated with centralization of this can-
cer care.
Beyond some demographic and medical features, 
relatively little is known about reproductive factors 
that may influence survival after OC diagnosis.5 In 
our study revealed women with postmenopausal 
had poorer OS scores than women with premeno-
pausal (p< 0.05). OC may be diagnosed earlier in 
premenopausal women than in postmenopausal 
women, because one major symptom used to iden-
tify OC is a change in menstruation. Premenopau-
sal women are also more likely to develop types 
of tumors that are easier to detect and therefore, 
the chances of survival are higher.18,22,23 Our results 
were similar previously reported in the literature 
but inconsistent with a population-based cohort 
study of Australian women that found no associa-
tion.20 
Comorbidities such as diabetes, heart disease and 
hypertension may impact this treatment disparity. 
The majority of studies show that comorbidities 
were found as the prognostic factors that influ-
ence the survival.6,18,28,29 In a different study20, a 
high comorbidity score of ≥2 was associated with 
a decreased OS rates (HR, 1.5 [95% CI, 1.1-2.1]). 
When we performed our analyses, we either did 
found a relationship, higher comorbidity score was 
found to have poorer OS. The results of our study 
are consistent with the literature.
Due to the prolonged OC course, obesity as poten-
tially modifiable risk factors may alter the survival. 
Suh et al30 reported that survival of OC was more 
influenced by the obese environment. In a different 
study25, obesity was found significant predictors of 
OS.  In this study similarly, overweight/obesity de-
fined as a BMI ≥25 kg/m2, demonstrated associa-
tion with worse OS. The role of obesity on survival 
both in the literature and in our results provides ev-
idence for women diagnosed with OC. Therefore, 
avoiding obesity in relation to treatment practices 
is the main strategy to improve the survival, as the 
health provider is expected to address obesity fac-
tors in developing a plan of care.
Some types of OC have a more favorable prog-
nosis. As reported in several studies, mucinous or 
clear-cell histology was associated with a worse 
OS compared with serous carcinomas.6,9,11,18,20 
Similar to others, we found that women with clear 
cell, endrometrioid and mucinous type had the 
poorest survival, possibly reflecting aggressive 
tumor biology or less sensitivity to routinely used 
chemotherapy. However, Benvito et23 and Shysas-
ree et al28 were not found of survival differences 
between subtypes and survival. Akhtar-Danesh et 
al22 reported that the worst survival observed for 
serous tumors.
In our study, low-grade tumor was associated with 
a more favorable prognosis than high-grade (p< 
0.05). Bodurka et al31 analyzed 378 women with 
low-grade tumors had significantly longer median 
DFS values than those with high-grade carcinomas 
(45.0 vs 19.8 months; p< 0.001). Similarly, other 
studies found that higher grade remained signifi-
cantly associated with survival.6,9,11,17,18,20,23 A mul-
tivariate analysis showed that, for OC, the histo-
logical grade was a significant prognostic factor 
for DFS but not for OS.19 As reported in several 
studies, grade as important prognostic factors is 
still controversial.
Matz et al8 analyzed data from 60 countries for 
695.932 women with OC during 2005-2009. 5-year 
OS ranged from 40 to 70% for type I localized epi-
thelial OC, for type II advanced epithelial tumors 
was much lower (20-45%). In a different study, the 
survival rates were higher for women with earlier 
stage cancers.9 We found that stage was the most 
important prognostic factor with regard to survival. 
Consistent with other work, we also revealed that 
high stage had significantly effect on OS (p< 0.05). 
In contrast, Shylasree et al28 analyzed the outcomes 
of 250 women with OC and there were no signifi-
cant differences regarding stage between OS. 
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Currently, there is no recommendation for rou-
tine OC screening from any national organization. 
Routinely checking markers and CT scans do not 
result in early detection or longer survival in either 
the general or high-risk populations.5 An elevated 
CA125 was not determinant factors of OS in our 
study (p> 0.05) in our study. Similar to the study 
of Whoo et al24 CA125 level was not influence on 
OS for OC. However we found that presence of 
recurrence had significant effect on survival in OC 
(p> 0.05). As mentioned in several studies the pa-
tients with recurrent had significantly shorter sur-
vival.24,29
Conclusion
In the result of this study, the 5-year survival for 
OC was 42.8%. The time of OS for patients was 
60.5 months and the median DFS rate was 18.3 
months, clearly reinforcing the need for preven-
tion, early detection and better treatments. Ad-
vanced age, subtype, recurrence, comorbidities, 
obesity, distance to residence, postmenopausal 
period, stage and grade were also associated with 
OS. Ideally, any prospective studies should be per-
formed on large number of patients to accurately 
establish whether geographic and socioeconomic 
differences, and medical features relate to survival. 
Until better screening tools are available, patient 
education and close follow-up remain the most im-
portant intervention for prevention of OC. Also, in-
dividualized healthcare may be able to determinant 
impact on survival for these women. 
Limitations
All of data from were a single hospital registry, 
thus not representative of the general population. 
However, this study was a maiden attempt to re-
veal that substantial prognostic factors of OC. 
Also, none of the studies looked at risk of some 
social factors such as regional distance or caregiver 
support, which would be important to those com-
missioning healthcare services.
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